Back to top

Spyre Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research

Wolfe Research downgraded Spyre Therapeutics (SYRE) to Peer Perform from Outperform without a price target The firm believes the shares are trading...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Spyre Therapeutics, Inc. (SYRE)